The influence of various glutamate receptors antagonists on anxiety-like effect of ethanol withdrawal in a plus-maze test in rats

European Journal of Pharmacology

Volumn 598, Issue 1-3, 2008, Pages 57-63

  Kotlinska, Jolanta ^a   Bochenski, Marcin ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Acamprosate; Anxiety; Behavior; Elevated plus maze; EMQMCM; Ethanol withdrawal; Memantine; mGlu receptor; MTEP; NMDA

Indexed keywords

3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; 3 ETHYL 2 METHYLQUINOLIN 6 YL (4 METHOXYCYCLOHEXYL)METHANONE METHANESULFONATE; ACAMPROSATE; ALCOHOL; GLUTAMATE RECEPTOR ANTAGONIST; MEMANTINE; UNCLASSIFIED DRUG;

ALCOHOL WITHDRAWAL; ALCOHOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; RELAPSE; TRANQUILIZING ACTIVITY; WISTAR RAT;

ALCOHOL DETERRENTS; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM DEPRESSANTS; ETHANOL; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MEMANTINE; PYRIDINES; QUINOLINES; RATS; RATS, WISTAR; RECEPTORS, GLUTAMATE; RECEPTORS, METABOTROPIC GLUTAMATE; SUBSTANCE WITHDRAWAL SYNDROME; TAURINE; THIAZOLES;

EID: 54049140827     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.09.026     Document Type: Article

References (82)

1. Anderson J.J., Bradbury M.J., Giracello D.R., Chapman D.F., Holtz G., Roppe J., King C., Cosford N.D., and Varney M.A. In vivo receptor occupancy of mGlu5 receptor antagonists using the novel radioligand [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine). Eur. J. Pharmacol. 473 (2003) 35-40
2. Anderson J.J., Rao S.P., Rowe B., Giracello D.R., Holtz G., Chapman D.F., Tehrani L., Bradbury M.J., Cosford N.D., and Varney M.A. [3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization. J. Pharmacol. Exp. Ther. 303 (2002) 1044-1051
3. Annis H.M., Sklar S.M., and Moser A.E. Gender in relation to relapse crisis situations, coping, and outcome among treated alcoholics. Addict. Behav. 23 (1998) 127-131
4. Baldwin H.A., Rassnick S., Rivier J., Koob G.F., and Britton K.T. CRF antagonist reverses the "anxiogenic" response to ethanol withdrawal in the rat. Psychopharmacology 103 (1991) 227-232
5. Bergink V., van Megen H.J., and Westenberg H.G. Glutamate and anxiety. Eur. Neuropsychopharmacol 14 (2004) 175-183
6. Berton F., Francesconi W.G., Madamba S.G., Zieglgänsberger W., and Siggins G.R. Acamprosate enhances N-methyl-d-apartate receptor-mediated neurotransmission but inhibits presynaptic GABA(B) receptors in nucleus accumbens neurons. Alcohol. Clin. Exp. Res. 22 (1998) 183-191
7. Bhattacharya S.K., Chakrabarti A., Sandler M., and Glover V. Rat brain monoamine oxidase A and B inhibitory (tribulin) activity during drug withdrawal anxiety. Neurosci. Lett. 199 (1995) 103-106
8. Biala G., and Kotlinska J. Blockade of the acquisition of ethanol-induced conditioned place preference by N-methyl-d-aspartate receptor antagonists. Alcohol Alcohol. 34 (1999) 175-182
9. Bisaga A., and Evans S.M. Acute effects of memantine in combination with alcohol in moderate drinkers. Psychopharmacology 172 (2004) 16-24
10. Broadbent J., and Weitemier A.Z. Dizocilpine (MK-801) prevents the development of sensitization to ethanol in DBA/2J mice. Alcohol Alcohol. 34 (1999) 283-288
11. Burattini C., McGeehan A.J., Griffin III W.C., Gass J.T., Kinder J.R., Janak P.H., and Olive M.F. A microdialysis study of extracellular levels of acamprosate and naltrexone in the rat brain following acute and repeated administration. Addict. Biol. 13 (2008) 70-79
12. Busse C.S., Brodkin J., Tattersall D., Anderson J.J., Warren N., Tehrani L., Bristow L.J., Varney M.A., and Cosford N.D. The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety. Neuropsychopharmacology 29 (2004) 1971-1979
13. Camarini R., Frussa-Filho R., Monteiro M.G., and Calil H.M. MK-801 blocks the development of behavioral sensitization to the ethanol. Alcohol. Clin. Exp. Res. 24 (2000) 285-290
14. Cole J.C., Littleton J.M., and Little H.J. Acamprosate, but not naltrexone, inhibits conditioned abstinence behaviour associated with repeated ethanol administration and exposure to a plus-maze. Psychopharmacology 147 (2000) 403-411
15. Cosford N.D., Roppe J., Tehrani L., Schweiger E.J., Seiders T.J., Chaudary A., Rao S., and Varney M.A. [3H]-methoxymethyl-MTEP and [3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. Bioorg. Med. Chem. Lett. 13 (2003) 351-354
16. Dahchour A., and De Witte P. Excitatory and inhibitory amino acid changes during repeated episodes of ethanol withdrawal: an in vivo microdialysis study. Eur. J. Pharmacol. 459 (2003) 171-178
17. De Soto C.B., O'Donnell W.E., and De Soto J.L. Long-term recovery in alcoholics. Alcohol. Clin. Exp. Res. 13 (1989) 693-697
18. De Witte P., Pinto E., Ansseau M., and Verbanck P. Alcohol and withdrawal: from animal research to clinical issues. Neurosci. Biobehav. Rev. 27 (2003) 189-197
19. Doremus T.L., Brunell S.C., Varlinskaya E.I., and Spear L.P. Anxiogenic effects during withdrawal from acute ethanol in adolescent and adult rats. Pharmacol. Biochem. Behav. 75 (2003) 411-418
20. Evans S.M., Levin F.R., Brooks D.J., and Garawi F. A pilot double-blind treatment trial of memantine for alcohol dependence. Alcohol. Clin. Exp. Res. 31 (2007) 775-782
21. Farook J.M., Krazem A., Lewis B., Morrell D.J., Littleton J.M., and Barron S. Acamprosate attenuates the handling induced convulsions during alcohol withdrawal in Swiss Webster mice. Physiol. Behav. 95 (2008) 267-270
22. File S.E. Chronic exposure to noise modifies the anxiogenic response, but not the hypoactivity, detected on withdrawal from chronic ethanol treatment. Psychopharmacology 116 (1994) 369-372
23. File S.E. Animal models of different anxiety states. In: Biggio G., Sanna E., and Costa E. (Eds). GABAa receptors and anxiety: From neurobiology to treatment (1995), Raven Press, New York 93-113
24. File S.E., and Andrews N. Low but not high doses of buspirone reduce the anxiogenic effects of diazepam withdrawal. Psychopharmacology 105 (1991) 578-582
25. File S.E., Andrews N., al-Farhan M., and Wu P.Y. The role of 5-HT in the anxiogenic effects of acute ethanol withdrawal and in the long-lasting cognitive deficits. Alcohol Alcohol. (Suppl) 2 (1993) 495-499
26. Gatch M.B., Wallis C.J., and Lal H. Effects of NMDA antagonists on ethanol-withdrawal induced "anxiety" in the elevated plus maze. Alcohol 19 (1999) 207-211
27. Grant K.A., Valverius P., Hudspith M., and Tabakoff B. Ethanol withdrawal seizures and the NMDA receptor complex. Eur. J. Pharmacol. 176 (1990) 289-296
28. Harris B.R., Prendergast M.A., Gibson D.A., Rogers D.T., Blanchard J.A., Holley R.C., Fu M.C., Hart S.R., Pedigo N.W., and Littleton J.M. Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol. Clin. Exp. Res. 26 (2002) 1779-1793
29. Hershon H.I. Alcohol withdrawal symptoms and drinking behavior. J. Stud. Alcohol 38 (1977) 953-971
30. Hodge C.W., Miles M.F., Sharko A.C., Stevenson R.A., Hillmann J.R., Lepoutre V., Besheer J., and Schroeder J.P. The mGluR5 antagonist MPEP selectively inhibits the onset and maintenance of ethanol self-administration in C57BL/6J mice. Psychopharmacology 183 (2006) 429-438
31. Hoffman P.L. Glutamate receptors in alcohol withdrawal-induced neurotoxicity. Metab. Brain Dis., 10 (1995) 73-79
32. Hoffman P.L., Iorio K.R., Snell L.D., and Tabakoff B. Attenuation of glutamate-induced neurotoxicity in chronically ethanol-exposed cerebellar granule cells by NMDA receptor antagonists and ganglioside GM1. Alcohol. Clin. Exp. Res. 19 (1995) 721-726
33. Hoffman P.L., Moses F., and Tabakoff B. Selective inhibition by ethanol of glutamate-stimulated cyclic GMP production in primary cultures of cerebellar granule cells. Neuropharmacology 28 (1989) 1239-1243
34. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148 (1991) 1301-1308
35. Karcz-Kubicha M., Jessa M., Nazar M., Plaznik A., Hartmann S., Parsons C.G., and Danysz W. Anxiolytic activity of glycine-B antagonists and partial agonists - no relation to intrinsic activity in the patch clamp. Neuropharmacology 36 (1997) 1355-1367
36. Kenny P.J., and Markou A. The ups and downs of addiction: role of metabotropic glutamate receptors. Trends Pharmacol. Sci. 25 (2004) 265-272
37. Kliethermes C.L. Anxiety-like behaviors following chronic ethanol exposure. Neurosci. Biobehav. Rev. 28 (2005) 837-850
38. Klodzinska A., Tatarczyńska E., Chojnacka-Wójcik E., Nowak G., Cosford N.D., and Pilc A. Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABA(A) signaling. Neuropharmacology 47 (2004) 342-350
39. Koob G.F., and Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24 (2001) 97-129
40. Koob G.F., and Le Moal M. Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. Nat. Neurosci. 8 (2005) 1442-1444
41. Koob G.F., Roberts A.J., Schulteis G., Parsons L.H., Heyser C.J., Hyytiä P., Merlo-Pich E., and Weiss F. Neurocircuitry targets in ethanol reward and dependence. Alcohol. Clin. Exp. Res., 22 (1998) 3-9
42. Kotlinska J., Biala G., Rafalski P., Bochenski M., and Danysz W. Effect of neramexane on ethanol dependence and reinforcement. Eur. J. Pharmacol. 503 (2004) 95-98
43. Kotlinska J., Bochenski M., and Danysz W. N-methyl-d-aspartate and group I metabotropic glutamate receptors are involved in the expression of ethanol-induced sensitization in mice. Behav. Pharmacol., 17 (2006) 1-8
44. Krupitsky E.M., Neznanova O., Masalov D., Burakov A.M., Didenko T., Romanova T., Tsoy M., Bespalov A., Slavina T.Y., Grinenko A.A., Petrakis I.L., Pittman B., Gueorguieva R., Zvartau E.E., and Krystal J.H. Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients. Am. J. Psychiatry 164 (2007) 519-523
45. Krupitsky E.M., Rudenko A.A., Burakov A.M., Slavina T.Y., Grinenko A.A., Pittman B., Gueorguieva R., Petrakis I.L., Zvartau E.E., and Krystal J.H. Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol. Clin. Exp. Res. 31 (2007) 604-611
46. Kushner M.G., Abrams K., Thuras P., Hanson K.L., Brekke M., and Sletten S. Follow-up study of anxiety disorder and alcohol dependence in comorbid alcoholism treatment patients. Alcohol. Clin. Exp. Res. 29 (2005) 1432-1443
47. Läck A.K., Diaz M.R., Chappell A., DuBois D.W., and McCool B.A. Chronic ethanol and withdrawal differentially modulate pre- and postsynaptic function at glutamatergic synapses in rat basolateral amygdala. J. Neurophysiol. 98 (2007) 3185-3196
48. Lhuintre J.P., Daoust M., Moore N.D., Chretien P., Saligaut C., Tran G., Bosimare F., and Hillemand B. Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet 1 (1985) 1014-1016
49. Lhuintre J.P., Moore N., Tran G., Steru L., Langrenon S., Daoust M., Parot P., Ladure P., Libert C., Boismare F., and Hillemand B. Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol. 25 (1990) 613-622
50. Littleton J. Acamprosate in alcohol dependence: how does it work?. Addiction 90 (1995) 1179-1188
51. Lominac K.D., Kapasova Z., Hannun R.A., Patterson C., Middaugh L.D., and Szumlinski K.K. Behavioral and neurochemical interactions between Group 1 mGluR antagonists and ethanol: potential insight into their anti-addictive properties. Drug Alcohol Depend. 85 (2006) 142-156
52. Lovinger D.M., White G., and Weight F.F. Ethanol inhibits NMDA-activated ion current in hippocampal neurons. Science 243 (1989) 1721-1724
53. Mayer S., Harris B.R., Gibson D.A., Blanchard J.A., Prendergast M.A., Holley R.C., and Littleton J. Acamprosate, MK-801, and ifenprodil inhibit neurotoxicity and calcium entry induced by ethanol withdrawal in organotypic slice cultures from neonatal rat hippocampus. Alcohol. Clin. Exp. Res. 26 (2002) 1468-1478
54. Michaelis E.K., Mulvaney M.J., and Freed W.J. Effects of acute and chronic ethanol intake on synaptosomal glutamate binding activity. Biochem. Pharmacol. 27 (1978) 1685-1691
55. Miller W.R., and Harris R.J. A simple scale of Gorski's warning signs for relapse. J. Stud. Alcohol 61 (2000) 759-765
56. Mossberg D., Liljeberg P., and Borg S. Clinical conditions in alcoholics during long-term abstinence: a descriptive, longitudinal treatment study. Alcohol 2 (1985) 551-553
57. Nagy J., Kolok S., Boros A., and Dezso P. Role of altered structure and function of NMDA receptors in development of alcohol dependence. Curr. Neuropharmacol. 3 (2005) 281-297
58. Olive M.F., and Becker H.C. Effects of the mGluR2/3 agonist LY379268 and the mGluR5 antagonist MPEP on handling-induced convulsions during ethanol withdrawal in mice. Alcohol 42 (2008) 191-197
59. Overstreet D.H., Knapp D.J., and Breese G.R. Accentuated decrease in social interaction in rats subjected to repeated ethanol withdrawals. Alcohol. Clin. Exp. Res. 26 (2002) 1259-1268
60. Pandey S.C., Zhang D., Mittal N., and Nayyar D. Potential role of the gene transcription factor cyclic AMP-responsive element binding protein in ethanol withdrawal-related anxiety. J. Pharmacol. Exp. Ther. 288 (1999) 866-878
61. Parsons C.G., Danysz W., Bartmann A., Spielmanns P., Frankiewicz T., Hesselink M., Eilbacher B., and Quack G. Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization. Neuropharmacology 38 (1999) 85-108
62. Parsons C.G., Danysz W., and Quack G. Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect. 11 (1998) 523-569
63. Parsons C.G., Stoffler A., and Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse. Neuropharmacology 53 (2007) 699-723
64. Pietraszek M., Sukhanov I., Maciejak P., Szyndler J., Gravius A., Wislowska A., Plaznik A., Bespalov A.Y., and Danysz W. Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats. Eur. J. Pharmacol. 514 (2005) 25-34
65. Popp R.L., and Lovinger D.M. Interaction of acamprosate with ethanol and spermine on NMDA receptors in primary cultured neurons. Eur. J. Pharmacol. 394 (2000) 221-231
66. Rammes G., Mahal B., Putzke J., Parsons C., Spielmanns P., Pestel E., Spanagel R., Zieglgansberger W., and Schadrack J. The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology 40 (2001) 749-760
67. Rodrigues S.M., Bauer E.P., Farb C.R., Schafe G.E., and LeDoux J.E. The group I metabotropic glutamate receptor mGluR5 is required for fear memory formation and long-term potentiation in the lateral amygdala. J. Neurosci. 22 (2002) 5219-5229
68. Schroeder J.P., Overstreet D.H., and Hodge C.W. The mGluR5 antagonist MPEP decreases operant ethanol self-administration during maintenance and after repeated alcohol deprivations in alcohol-preferring (P) rats. Psychopharmacology 179 (2005) 262-270
69. Schulteis G., and Liu J. Brain reward deficits accompany withdrawal (hangover) from acute ethanol in rats. Alcohol 39 (2006) 21-28
70. Schulteis G., Markou A., Cole M., and Koob G.F. Decreased brain reward produced by ethanol withdrawal. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 5880-5884
71. Schulz B., Fendt M., Gasparini F., Lingenhöhl K., Kuhn R., and Koch M. The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) blocks fear conditioning in rats. Neuropharmacology 41 (2001) 1-7
72. Simon A.B., and Gorman J.M. Advances in the treatment of anxiety: targeting glutamate. NeuroRx. 3 (2006) 57-68
73. Snell L.D., Tabakoff B., and Hoffman P.L. Radioligand binding to the N-methyl-d-aspartate receptor/ionophore complex: alterations by ethanol in vitro and by chronic in vivo ethanol ingestion. Brain Res. 602 (1993) 91-98
74. Spanagel R., Hölter S.M., Allingham K., Landgraf R., and Zieglgänsberger W. Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat. Eur. J. Pharmacol. 305 (1996) 39-44
75. Spooren W.P., Vassout A., Neijt H.C., Kuhn R., Gasparini F., Roux S., Porsolt R.D., and Gentsch C. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J. Pharmacol. Exp. Ther. 295 (2000) 1267-1275
76. Tatarczyńska E., Klodzińska A., Chojnacka-Wójcik E., Palucha A., Gasparini F., Kuhn R., and Pilc A. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br. J. Pharmacol. 132 (2001) 1423-1430
77. Valdez G.R., Roberts A.J., Chan K., Davis H., Brennan M., Zorrilla E.P., and Koob G.F. Increased ethanol self-administration and anxiety-like behavior during acute ethanol withdrawal and protracted abstinence: regulation by corticotropin-releasing factor. Alcohol. Clin. Exp. Res. 26 (2002) 1494-1501
78. Varty G.B., Grilli M., Forlani A., Fredduzzi S., Grzelak M.E., Guthrie D.H., Hodgson R.A., Lu S.X., Nicolussi E., Pond A.J., Parker E.M., Hunter J.C., Higgins G.A., Reggiani A., and Bertorelli R. The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles. Psychopharmacology 179 (2005) 207-217
79. Weiss F., Ciccocioppo R., Parsons L.H., Katner S., Liu X., Zorrilla E.P., Valdez G.R., Ben-Shaher O., Anageletti S., and Richter R.R. Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors. Ann. N. Y. Acad. Sci., 937 (2001) 1-26
80. Wenk G.L., Parsons C.G., and Danysz W. Potential role of N-methyl-d-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. Behav. Pharmacol., 17 (2006) 411-424
81. Willinger U., Lenzinger E., Hornik K., Fischer G., Schönbeck G., Aschauer H.N., and Meszaros K. European fluvoxamine in alcoholism study group. Anxiety as a predictor of relapse in detoxified alcohol-dependent patients. Alcohol Alcohol. 37 (2002) 609-612
82. Zhang Z., Morse A.C., Koob G.F., and Schulteis G. Dose- and time-dependent expression of anxiety-like behavior in the elevated plus-maze during withdrawal from acute and repeated intermittent ethanol intoxication in rats. Alcohol. Clin. Exp. Res. 31 (2007) 1811-1819